Re: owl:sameAs - Harmful to provenance?

2013-04-03 Thread Pat Hayes
On Apr 3, 2013, at 9:00 PM, Peter Ansell wrote: > On 4 April 2013 11:58, David Booth wrote: > On 04/02/2013 05:02 PM, Alan Ruttenberg wrote: > On Tuesday, April 2, 2013, David Booth wrote: > On 03/27/2013 10:56 PM, Pat Hayes wrote: > On Mar 27, 2013, at 7:32 PM, Jim McCusker wrote: >

Re: owl:sameAs - Harmful to provenance?

2013-04-03 Thread Alan Ruttenberg
Dropping Jim from cc in deference to him finishing his defense. On Wed, Apr 3, 2013 at 9:58 PM, David Booth wrote: > On 04/02/2013 05:02 PM, Alan Ruttenberg wrote: > >> On Tuesday, April 2, 2013, David Booth wrote: >> On 03/27/2013 10:56 PM, Pat Hayes wrote: >> On Mar 27, 2013, at 7:

Re: owl:sameAs - Harmful to provenance?

2013-04-03 Thread Peter Ansell
On 4 April 2013 11:58, David Booth wrote: > On 04/02/2013 05:02 PM, Alan Ruttenberg wrote: > >> On Tuesday, April 2, 2013, David Booth wrote: >> On 03/27/2013 10:56 PM, Pat Hayes wrote: >> On Mar 27, 2013, at 7:32 PM, Jim McCusker wrote: >> >> If only owl:sameAs were used

Re: owl:sameAs - Harmful to provenance?

2013-04-03 Thread David Booth
On 04/02/2013 05:02 PM, Alan Ruttenberg wrote: On Tuesday, April 2, 2013, David Booth wrote: On 03/27/2013 10:56 PM, Pat Hayes wrote: On Mar 27, 2013, at 7:32 PM, Jim McCusker wrote: If only owl:sameAs were used correctly... Well, I agree that is a problem, but d

Re: VCF and RDF, at Clinical Pharmacogenomics TF, Wed Apr 3rd

2013-04-03 Thread Jeremy J Carroll
Thanks Michael this is helpful, we are thinking about various ways of selecting what gets mapped … While it is blindingly obvious that to each person looking at a VCF file "the vast majority are going to turn out to be uninteresting" the difficulty I am having is whether we (as essentially a

Re: blank nodes ….

2013-04-03 Thread David Booth
Hi Jeremy, I worked with genomic data very similar to yours, and initially used blank nodes for exactly the purpose that you describe below. However, I regretted doing so when I realized that every time I loaded some of the same source data, duplicate triples were added, because the system di

RE: VCF and RDF, at Clinical Pharmacogenomics TF, Wed Apr 3rd

2013-04-03 Thread Michael Miller
hi jeremy, sorry i missed your talk this morning, it was early on the west coast. 'I am assuming that the data lines can largely be addressed by reading the INFO, FORMAT and FILTER definitions at the top of the file, and handling appropriately' yes, certainly for the standard annotations b

Re: blank nodes ….

2013-04-03 Thread Kingsley Idehen
On 4/3/13 4:07 PM, Michel Dumontier wrote: The major motivation for avoiding blank nodes is that you cannot reliably refer to those objects from outside the dataset. It precludes any kind of linking or argumentation. Yes, I know that re., Linked Data scenarios :-) In Bio2RDF, we generate URIs

Re: blank nodes ….

2013-04-03 Thread Michel Dumontier
The major motivation for avoiding blank nodes is that you cannot reliably refer to those objects from outside the dataset. It precludes any kind of linking or argumentation. In Bio2RDF, we generate URIs for all objects, and use the identifier when provided, otherwise we generate one when there is n

Re: blank nodes ….

2013-04-03 Thread Kingsley Idehen
On 4/3/13 3:12 PM, Jeremy J Carroll wrote: >There is, I think, a sustainable argument that blank nodes are not*necessary*. I beg to differ. Blank nodes are absolutely necessary. "Horses for courses" again. Blank nodes are only problematic when misunderstood and used inappropriately. No diffe

blank nodes ….

2013-04-03 Thread Jeremy J Carroll
One question that I didn't really answer today was about my choice to use blank nodes extensively following http://www.w3.org/TR/swbp-n-aryRelations/ [[ we did not give meaningful names to instances of properties or to the classes used to represent instances of n-ary relations, but merely la

Re: Meeting minutes: Clinical Pharmacogenomics Teleconference

2013-04-03 Thread Pathak, Jyotishman, Ph.D.
Joanne, Matthias and all, As you know may know, Mayo Clinic is one of the NIH designated Pharmacogenomics Research Network (PGRN) site, and pharmacogenomics of Major Depressive Disorder is one of the main focus. Our team has made significant progress in developing EHR-based treatment response a

Deadline approaching: International Workshop on Definitions in Ontologies (DO 2013)

2013-04-03 Thread Selja Seppälä
Apologies for cross-posting Please forward this message to any potential colleagues in the areas of interest DEADLINE APPROACHING International Workshop on Definitions in Ontologies (DO 2013) July 7, 2013 At ICBO 2013 (International Conference on Biomedical Ontologies) Montreal, Canada Website:

Re: Meeting minutes: Clinical Pharmacogenomics Teleconference

2013-04-03 Thread Joanne Luciano
Thanks for this. I am sorry I was unable to make the meeting today. I had two others going on at the same time! I'm interested in following up on the Depression work (thanks Bob Powers for the Skype note) and will follow-up next week. Kind regards, Joanne On Apr 3, 2013, at 11:32 AM, Matthias S

Meeting minutes: Clinical Pharmacogenomics Teleconference

2013-04-03 Thread Matthias Samwald
The meeting minutes are available at http://www.w3.org/2013/04/03-HCLS-minutes.html Cheers, Matthias From: Matthias Samwald Sent: Wednesday, April 03, 2013 2:56 PM To: public-semweb-lifesci@w3.org Subject: Reminder: Clinical Pharmacogenomics Teleconference This is a reminder of the Clinical

Reminder: Clinical Pharmacogenomics Teleconference

2013-04-03 Thread Matthias Samwald
This is a reminder of the Clinical Pharmacogenomics Teleconference today at 10:15 Eastern Time (16:15 Central European Time). Here is the suggested agenda: a.. Jeremy Carroll will present his work on VCF and RDF. a.. Presentation slides: http://lists.w3.org/Archives/Public/www-archive/2013